Hemoglobinopathy

Global Market Trajectory & Analytics

MCP12343

EXECUTIVE ENGAGEMENTS

POOL

1267
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

228
Interactions with Platform & by Email

PARTICIPANTS

51
Unique # Participated

VALIDATIONS

13
Responses Validated*

COMPANIES

38
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

159

PAGES

227

EDITION

9

PRICE

USD 4950

CODE

MCP12343


COMPETITIVE METRICS

COMPANY

D S N T

% *

Bio-Rad Laboratories, Inc.

Danaher Corporation

Errant Gene Therapeutics LLC

Imara

Mindray Medical International Ltd.

Nexcelom Bioscience LLC

Nihon Kohden Corporation

PerkinElmer, Inc.

Sangamo Therapeutics, Inc.

View More...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Hemoglobinopathy estimated at US$517.2 Million in the year 2020, is projected to reach a revised size of US$823.4 Million by 2027, growing at a CAGR of 6.9% over the analysis period 2020-2027. Sickle Cell Disease, one of the segments analyzed in the report, is projected to record a 6.5% CAGR and reach US$449.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Beta Thalassemia segment is readjusted to a revised 7.1% CAGR for the next 7-year period.
The Hemoglobinopathy market in the U.S. is estimated at US$152.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$144.5 Million by the year 2027 trailing a CAGR of 6.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.5% and 5.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.
In the global Alpha Thalassemia segment, USA, Canada, Japan, China and Europe will drive the 8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$60 Million in the year 2020 will reach a projected size of US$102.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$95.2 Million by the year 2027.

SELECT PLAYERS

Abbott Diagnostics; Bio-Rad Laboratories, Inc.; Danaher Corporation; Mindray Medical International Ltd.; Nexcelom Bioscience LLC; Nihon Kohden Corporation; PerkinElmer, Inc.; Siemens Healthineers; Sysmex Europe GmbH

SEGMENTS

» End-Use (Hospitals, Diagnostics Laboratories, Clinics) » Indication (Sickle Cell Disease, Beta Thalassemia, Alpha Thalassemia) » Test Type (Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP, Other Test Types)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Hemoglobinopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Hemoglobinopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hemoglobinopathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Sickle Cell Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Beta Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Beta Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Beta Thalassemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Alpha Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Alpha Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Alpha Thalassemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Diagnostics Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Diagnostics Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Diagnostics Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Routine Red Blood Cell (RBC) Count by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Routine Red Blood Cell (RBC) Count by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Routine Red Blood Cell (RBC) Count by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Hb IEF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Hb IEF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hb IEF by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Hb ELP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Hb ELP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hb ELP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Hemoglobinopathy by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Hemoglobinopathy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Hemoglobinopathy by Test Type - Percentage Breakdown of Value Sales for Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Hemoglobinopathy by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Hemoglobinopathy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Hemoglobinopathy by Test Type - Percentage Breakdown of Value Sales for Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Hemoglobinopathy by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Hemoglobinopathy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Hemoglobinopathy by Test Type - Percentage Breakdown of Value Sales for Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Hemoglobinopathy by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2012, 2020 & 2027
China Current & Future Analysis for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Hemoglobinopathy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2012, 2020 & 2027
China Current & Future Analysis for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Hemoglobinopathy by Test Type - Percentage Breakdown of Value Sales for Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Hemoglobinopathy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Hemoglobinopathy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Hemoglobinopathy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Hemoglobinopathy by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Hemoglobinopathy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Hemoglobinopathy by Test Type - Percentage Breakdown of Value Sales for Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Hemoglobinopathy by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2012, 2020 & 2027
France Current & Future Analysis for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Hemoglobinopathy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2012, 2020 & 2027
France Current & Future Analysis for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Hemoglobinopathy by Test Type - Percentage Breakdown of Value Sales for Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Hemoglobinopathy by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Hemoglobinopathy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Hemoglobinopathy by Test Type - Percentage Breakdown of Value Sales for Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Hemoglobinopathy by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Hemoglobinopathy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Hemoglobinopathy by Test Type - Percentage Breakdown of Value Sales for Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Hemoglobinopathy by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Hemoglobinopathy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Hemoglobinopathy by Test Type - Percentage Breakdown of Value Sales for Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Hemoglobinopathy by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Hemoglobinopathy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Hemoglobinopathy by Test Type - Percentage Breakdown of Value Sales for Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Hemoglobinopathy by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Hemoglobinopathy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Hemoglobinopathy by Test Type - Percentage Breakdown of Value Sales for Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Hemoglobinopathy by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Hemoglobinopathy by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Hemoglobinopathy by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Hemoglobinopathy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Hemoglobinopathy by Test Type - Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Hemoglobinopathy by Test Type - Percentage Breakdown of Value Sales for Routine Red Blood Cell (RBC) Count, Genetic Testing, Hb IEF, Hb ELP and Other Test Types for the Years 2012, 2020 & 2027
Total Companies Profiled: 38

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com